GLA/alpha-Galactosidase A, Mouse, 重组蛋白 (His) TMPY-02857

Product Introduction
Bioactivity


英文名: GLA/alpha-Galactosidase A Protein, Mouse, Recombinant (His)

描述: Alpha-galactosidase A, also known as Alpha-D-galactoside galactohydrolase, Alpha-D-galactosidase A, Melibiase and GLA, is a member of the glycosyl hydrolase 27 family. GLA is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Defects in GLA are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Deficiency of GLA leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction.

存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month

GLA/alpha-Galactosidase A, Mouse, 重组蛋白 (His) TMPY-02857信息由TargetMol中国为您提供，如您想了解更多关于GLA/alpha-Galactosidase A, Mouse, 重组蛋白 (His) TMPY-02857报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途